Old sedative, new trick: amobarbital may shield the heart during bypass surgery
NCT ID NCT06757868
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial investigates whether a single dose of amobarbital, an older sedative, can protect the heart muscle in adults undergoing cardiac surgery with a heart-lung machine. Researchers will measure how quickly the heart restarts after bypass and track recovery times and heart damage markers. The goal is to see if this inexpensive drug can improve surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amobarbital
- What this could lead to
- If it works, this could point toward a simple, low-cost way to protect the heart during surgery and speed up recovery.
- What could go wrong
- This is a small, early-stage trial with 80 people, so results may not apply to everyone. Amobarbital is a sedative and may cause side effects like drowsiness or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji hospital
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Calcium timing during bypass may cut need for heart drugs
- Double nerve block may ease pain and speed recovery after heart surgery
- New dashboard aims to give surgeons a complete view during heart surgery
- Could a simple nerve block transform heart surgery recovery?
- Could a softer Heart-Lung machine protect the brain during surgery?
- Smarter transfusions: tailoring blood use after heart surgery